Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effects of Glycine on Symptoms and Memory in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males aged 18-65 with DSM-IV diagnosis of schizophrenia or schizoaffective disorder by diagnostic interview and chart review~2. Clinically stable on a stable dose of antipsychotic medication (any except clozapine or olanzapine) for at least one month, no current active suicidal ideation~3. Not treated with investigational medication in the past 30 days~4. Competent to provide informed consent~Exclusion Criteria:~1. Diagnosis of dementia, neurodegenerative disease, seizure disorder, current substance abuse or dependence disorders, including alcohol, active within the last 3 months or any Axis I DSM-IV diagnosis other than schizophrenia or schizoaffective disorder~2. Serious illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease that is not stabilized such that hospitalization for treatment of that illness is likely within the next four months~3. Patients who, in the investigator's opinion, pose a current severe homicide or suicide risk~4. History of multiple head injuries with neurological sequelae or a single severe head injury with lasting neurological sequelae~5. Uncontrolled hypertension~6. Anuretic~7. Use of clozapine or olanzapine in the past month~8. Subjects who weigh more than 275 lbs~9. Subjects who are claustrophobic~10. Subjects with a history of electrolyte imbalance~11. Subjects who have lost consciousness for 30 minutes or more~12. Subjects with lifetime history of stroke~13. Subjects with myocardial infarction within the last 6 months~14. Those having a pacemaker or a heart arrhythmia~15. Source of metal in body incompatible with MRI procedures~16. Those who have ever used a dietary glycine supplement

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).